Company intelligence / Profile preview

CODA Biotherapeutics

South San Francisco, California, United Statesbiospace.com ↗

Ownership: Private
Development stage: Preclinical

Overview

CODA developed a chemogenetic gene therapy platform aiming to treat intractable neurological diseases by enabling precise control over neuronal activity. The approach involved engineering neurons to express ligand-gated ion channels that could be activated or silenced by proprietary small molecules. Initial clinical results were not published before the company closed; no programs advanced beyond preclinical/early clinical stages publicly.

Therapeutic areas: PulmonologyNeurology
Modalities: Gene therapyChemogeneticsSmall molecules (as activators for engineered receptors)
Industry: Biotech

Partnerships

Versant Ventures and MPM Capital were co-launch partners/investors but no major pharma partnerships disclosed.

Beyond the preview

Go deeper on CODA Biotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CODA Biotherapeutics.

Explore the full profile